{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:00:58Z","timestamp":1747206058656,"version":"3.40.5"},"reference-count":46,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s317885","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T17:40:45Z","timestamp":1626889245000},"page":"661-671","source":"Crossref","is-referenced-by-count":0,"title":["Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate\u2013High Risk: A Cost-Effectiveness Analysis"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Marco","family":"Bellone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-8917","authenticated-orcid":true,"given":"Lorenzo","family":"Pradelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Molica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele Emanuela","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Ghislieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Guardalben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.canep.2015.08.015","volume":"39","author":"Smith","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"ref4","unstructured":"European Medicines Agency. European Medicines Agency: public Summary of Opinion on Orphan Designation: obinutuzumab for the treatment of follicular lymphoma 23 July 2015. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/15\/1504-public-summary-opinion-orphan-designation-obinutuzumab-treatment-follicular-lymphoma_en.pdf. Accessed January, 2020."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19191\/EP16.1S2.P001.035","volume":"40","author":"Busco","year":"2016","journal-title":"Epidemiol Prev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.cmonc.2012.09.015","volume":"9","author":"Nastoupil","year":"2012","journal-title":"Community Oncol"},{"key":"ref7","unstructured":"AIOM. Linee guida linfomi [Lymphoma guidelines]. Edizione 2018. Available from: https:\/\/www.aiom.it\/linee-guida-aiom-2018-linfomi\/. Accessed April 8, 2021."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/asheducation-2007.1.216","author":"Salles","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5581\/1516-8484.20120015","volume":"34","author":"Luminari","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16370","volume":"16","author":"Papaioannou","year":"2012","journal-title":"Health Technol Assess"},{"key":"ref14","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines B-Cell Lymphoma. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed April 8, 2021."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref17","unstructured":"European Medicines Agency. Gazyvaro\u00ae - Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gazyvaro-epar-product-information_en.pdf. Accessed April 8, 2021."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/009286150103500122","volume":"35","author":"Capri","year":"2001","journal-title":"Drug Inf J"},{"key":"ref25","first-page":"303","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/hon.56_2631","volume":"37","author":"Launonen","year":"2019","journal-title":"Hematol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jval.2013.04.008","volume":"16","author":"Scalone","year":"2013","journal-title":"Value Health"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"volume-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","year":"2014","key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1"},{"key":"ref31","unstructured":"European Medicines Agency. Rituximab - Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera. Accessed April 8, 2021."},{"key":"ref32","unstructured":"SORESA. SORESA anagrafica beni (28-08-2020). Available from: www.soresa.it. Accessed April 8, 2020."},{"key":"ref33","unstructured":"Roche Market Research. Data On-File."},{"volume-title":"Remunerazione Prestazioni Di Assistenza Ospedaliera per Acuti, Assistenza Ospedaliera Di Riabilitazione e Di Lungodegenza Post Acuzie e Di Assistenza Specialistica Ambulatoriale","key":"ref34"},{"volume-title":"Pharmaceutical Market Access in Deleveloped Markets","key":"ref35"},{"key":"ref36","unstructured":"dei Ministri PD. La conferenza permanente per i rapporti tra lo Stato, le Regioni e le Provincie Autonome di Trento e Bolzano. 189\/CSR of 18\/10\/2018."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref38","unstructured":"AIMAC. I Linfomi Non Hodgkin [Understanding Non-Hodgkin\u2019s Lymphomas] (No. 18). La Collana del Girasole; 2015. Available from: https:\/\/www.aimac.it\/libretti-tumore\/linfomi-non-hodgkin. Accessed July 2019."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjc.6605417","volume":"102","author":"Mickisch","year":"2010","journal-title":"Br J Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1524-4733.2007.00302.x","volume":"11","author":"Brown","year":"2008","journal-title":"Value Health"},{"key":"ref43","unstructured":"Direzione generale della programmazione sanitaria - Ufficio 6. Ministero della Salute (2018). Rapporto annuale sull\u2019attivit\u00e0 di ricovero ospedaliero (SDO). Available from: https:\/\/www.salute.gov.it\/portale\/documentazione\/p6_2_2_1.jsp?lingua=italiano&id=2898. Accessed July 2020."},{"key":"ref44","first-page":"53","volume":"5","author":"Messori","year":"2003","journal-title":"Pharmaco Econ"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jval.2018.09.224","volume":"21","author":"Vellopoulou","year":"2018","journal-title":"Value in Health"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2217\/cer-2020-0131","volume":"9","author":"Hofmann","year":"2020","journal-title":"J Comp Eff Res"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71939","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T17:41:05Z","timestamp":1626889265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/obinutuzumab-plus-chemotherapy-compared-with-rituximab-plus-chemothera-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":46,"URL":"https:\/\/doi.org\/10.2147\/ceor.s317885","relation":{},"ISSN":["1178-6981"],"issn-type":[{"type":"electronic","value":"1178-6981"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}